Get the Stockscreener App
4.47
1.32%
-0.06
Pre-market:
4.41
-0.06
-1.34%
Macrogenics Inc stock is traded at $4.47, with a volume of 1.05M.
It is down -1.32% in the last 24 hours and up +40.13% over the past month.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
See More
Previous Close:
$4.53
Open:
$4.5
24h Volume:
1.05M
Relative Volume:
0.83
Market Cap:
$284.13M
Revenue:
$149.50M
Net Income/Loss:
$-74.62M
P/E Ratio:
-3.7763
EPS:
-1.1837
Net Cash Flow:
$-82.95M
1W Performance:
-1.11%
1M Performance:
+40.13%
6M Performance:
+202.03%
1Y Performance:
+196.03%
1-Day Range:
$4.30
$4.515
1-Week Range:
$4.235
$4.6401
52-Week Range:
$1.185
$4.6401
Macrogenics Inc Stock (MGNX) Company Profile
Name
Macrogenics Inc
Sector
Industry
Phone
301-251-5172
Address
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
4.47 | 287.94M | 149.50M | -74.62M | -82.95M | -1.1837 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Upgrade | B. Riley Securities | Neutral → Buy |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Nov-07-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Aug-01-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-31-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| May-10-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-10-24 | Downgrade | Stifel | Buy → Hold |
| May-10-24 | Downgrade | TD Cowen | Buy → Hold |
| Apr-26-24 | Initiated | B. Riley Securities | Buy |
| Apr-09-24 | Upgrade | TD Cowen | Hold → Buy |
| Mar-04-24 | Reiterated | BTIG Research | Buy |
| Feb-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-22-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-14-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-18-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Jul-11-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-04-22 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-28-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-04-22 | Initiated | SMBC Nikko | Outperform |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Upgrade | Barclays | Underweight → Overweight |
| Dec-22-20 | Resumed | H.C. Wainwright | Buy |
| Aug-03-20 | Downgrade | Citigroup | Buy → Neutral |
| Jun-01-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-26-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Dec-19-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-19 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-21-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Guggenheim | Neutral |
| Feb-07-19 | Upgrade | Citigroup | Sell → Buy |
| Feb-07-19 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-06-19 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-04-19 | Downgrade | Citigroup | Neutral → Sell |
| Dec-10-18 | Downgrade | Raymond James | Outperform → Underperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| May-31-18 | Initiated | Evercore ISI | Outperform |
| Mar-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-31-17 | Initiated | Raymond James | Outperform |
View All
Macrogenics Inc Stock (MGNX) Latest News
MacroGenics to sell manufacturing operations to Bora for $122.5M - MSN
MacroGenics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
How The MacroGenics (MGNX) Story Is Shifting With ADC Hopes And Execution Risks - Yahoo Finance
MacroGenics stock (US5562221046): insider equity grants follow 2026 shareholder meeting - AD HOC NEWS
MacroGenics Shareholders Back Board, Auditors and Equity Plan - TipRanks
MACROGENICS (MGNX) director O'Brien receives RSUs and 22,000-share option grant - Stock Titan
MacroGenics (MGNX) director receives new options and RSU awards - Stock Titan
MacroGenics (MGNX) director granted options, RSUs and stock - Stock Titan
MacroGenics (MGNX) director converts 3,750 RSUs into common shares - Stock Titan
MacroGenics (MGNX) director awarded options, RSUs and exercises prior grant - Stock Titan
MACROGENICS (MGNX) director Meenu Chhabra gets RSUs, options and RSU vesting - Stock Titan
MACROGENICS (MGNX) director granted options, RSUs and exercises awards - Stock Titan
MACROGENICS (MGNX) director David C. Stump gets new options and RSUs - Stock Titan
MacroGenics (MGNX) director granted options and RSUs, RSUs vest into shares - Stock Titan
MacroGenics (MGNX) awards stock options and RSUs to director Koenig - Stock Titan
MacroGenics (MGNX) investors back board slate and expand 2023 equity plan - Stock Titan
MacroGenics stock (US5562221046): biotech shares jump after Vyloy FDA approval and takeover deal - AD HOC NEWS
Macrogenics (MGNX) News Flow - Moomoo
Macrogenics(MGNX) Stock Options Chain | Quotes & News - Moomoo
MacroGenics stock (US5562221046): FDA hold lifted and shares among May’s biotech gainers - AD HOC NEWS
MacroGenics (MGNX) price target increased by 50.00% to 6.12 - MSN
MacroGenics gains removal of FDA partial hold on lead program - MSN
Bora Group to acquire MacroGenics manufacturing for 122.5 million - MSN
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Beha - GuruFocus
Bora to acquire MacroGenics‘ biologics manufacturing facility in Maryland - megaproject.com
MacroGenics sells manufacturing arm to Bora in $123m deal - The Pharma Letter
MacroGenics, Inc.Common Stock (NQ: MGNX - The Chronicle-Journal
Armistice Capital (MGNX) reports 6.01M-share, 9.46% stake in Macrogenics - Stock Titan
MacroGenics, Inc. (NASDAQ:MGNX) Analysts Are Pretty Bullish On The Stock After Recent Results - Yahoo Finance
MacroGenics Reaches US$219m Market Cap Benefiting Insider Stock Buying - Moomoo
Millennium Group reports 3.07M-share stake in MacroGenics (MGNX) - Stock Titan
Bank of America (NASDAQ: MGNX) reports 5.1% ownership in MacroGenics - Stock Titan
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum - The Manila Times
Macrogenics Cash, Cash Equivalents and Marketable Securities Balance of $154.2 M as of March 31 >MGNX - Moomoo
Stifel Maintains Macrogenics(MGNX.US) With Hold Rating, Maintains Target Price $4 - Moomoo
Bora Pharmaceuticals to Acquire MacroGenics Manufacturing Facility in $122.5 Million Deal - biobuzz.io
Barclays Maintains Macrogenics(MGNX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Key facts: MacroGenics Q1 +58% revenue; $36.8M loss; LINNET 4 responses - TradingView
MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation - The Manila Times
Is MacroGenics (MGNX) 10.6% Undervalued After Q1 2026 Beat? EPS - GuruFocus
MacroGenics (MGNX) reports Q1 loss, tops revenue estimates - MSN
MacroGenics Inc earnings missed by $0.01, revenue topped estimates - Investing.com South Africa
MacroGenics (MGNX) Reports Strong Q1 Revenue and Strategic Movem - GuruFocus
MacroGenics Inc earnings missed by $0.01, revenue topped estimates By Investing.com - Investing.com India
MGNX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
MacroGenics (MGNX) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
MacroGenics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MacroGenics : Reports First Quarter 2026 Financial Results and Highlights Business Transformation Manufacturing operations divestiture sharpens focus on core capabilities in novel drug discovery and development Manufacturing divestiture and expanded m - marketscreener.com
MacroGenics reports Q1 2026 loss of $36.8M; revenue rises to $20.8M, cash runway extended through 2028 - TradingView
MACROGENICS ($MGNX) Releases Q1 2026 Earnings - Quiver Quantitative
MacroGenics: Q1 Earnings Snapshot - marketscreener.com
Macrogenics Inc Stock (MGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):